Creoptix
Creoptix is a Switzerland-based brand of Malvern Panalytical that develops the WAVE bioanalytical instrument and microfluidic consumables, using proprietary GCI technology for label-free molecular interaction analysis in drug discovery and life sciences R&D, serving pharmaceutical, biotech, and academic customers.
- Company typePrivate
- Founded2022
- HeadquartersWadenswil, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Creoptix does
Creoptix is a Swiss-headquartered life sciences instrumentation company that develops optical instruments and consumables for the label-free analysis of molecular interactions, serving pharmaceutical, biotechnology, and academic research customers in drug discovery and life sciences R&D. Its core product, the Creoptix WAVE, is a next-generation bioanalytical instrument built on proprietary Grating-Coupled Interferometry (GCI) biosensor technology, paired with custom no-clog WAVEchip microfluidic sensor chips and the WAVEcontrol software suite (including Direct Kinetics and waveRAPID modules). The system is designed to deliver high sensitivity and resolution for real-time kinetic characterization of fragments, small molecules, peptides, membrane proteins, and biologics, including analysis in crude reaction mixtures and undiluted biofluids such as serum and plasma — a workflow advantage versus traditional SPR-based platforms.
The company's revenue model combines capital instrument sales with recurring WAVEchip consumables, software licenses, and professional services such as training and technical support. Creoptix operates an enterprise B2B go-to-market, historically direct and now executed primarily through Malvern Panalytical's global field-sales organization, regional offices (including Boston for North America), and the Mystore e-commerce platform. Since the January 2022 integration into Malvern Panalytical — itself a subsidiary of UK-listed Spectris plc — Creoptix has functioned as a brand within a larger analytical instrumentation portfolio, targeting pharmaceutical and biotechnology firms as the primary vertical and academic research institutions as a secondary segment.
Creoptix firmographics
Firmographics- Name
- Creoptix
- Legal name
- Creoptix (Malvern Panalytical brand)
- Website
- https://creoptix.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Creoptix is a Switzerland-based brand of Malvern Panalytical that develops the WAVE bioanalytical instrument and microfluidic consumables, using proprietary GCI technology for label-free molecular interaction analysis in drug discovery and life sciences R&D, serving pharmaceutical, biotech, and academic customers.
- Ownership category
- akta.pro rank
Creoptix industry classification
Industry- Product category
- Bioanalytical Instruments
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
- akta.pro primary industry
- Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)
Keywords
Where Creoptix is headquartered
LocationHeadquarters
- HQ city
- Wadenswil
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
Creoptix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Bioanalytical Instruments (Hardware): Sale of the Creoptix WAVE next-generation bioanalytical instrument system for molecular interaction analysis in drug discovery and life sciences research.
- Sensor Chips and Consumables: WAVEchip microfluidic sensor chips designed for specific analytical needs, providing recurring consumables revenue.
- Software Licenses and Support: Software products including WAVEcontrol, Direct Kinetics, and waveRAPID with associated support services.
- Professional Services: Product support, training, and technical services for instrument installation and operation.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Creoptix product offering
Product offeringCore offering
Creoptix develops and sells the WAVE next-generation bioanalytical instrument, a label-free optical biosensor system based on proprietary Grating-Coupled Interferometry (GCI) for real-time molecular interaction analysis in drug discovery and life sciences research. The company also supplies WAVEchip microfluidic sensor chips as consumables and WAVEcontrol software for instrument control and data analysis, serving pharmaceutical, biotechnology, and academic research customers.
Product overview
Creoptix is a Malvern Panalytical brand offering a unified product portfolio centered on the Creoptix WAVE platform — a next-generation bioanalytical instrument for molecular interaction analysis. The WAVEsystem serves as the core product, supported by WAVEchip (microfluidic sensor chips), WAVEcontrol software (instrument control and data analysis), Direct Kinetics (1-click kinetic evaluation), and waveRAPID (kinetic measurement technique). Proprietary technologies include Grating-Coupled Interferometry (GCI) for high-sensitivity biophysical characterization and advanced microfluidics for sample compatibility. The portfolio is designed for drug discovery and life sciences research, enabling real-time analysis of molecular interactions across fragment, small molecule, peptide, membrane protein, and biologic targets in complex matrices.
Differentiator
Problem solved
Functional benefit
Brands
- WAVEsystem: Next-generation bioanalytical instrument system for molecular interaction analysis
- WAVEchip
- WAVEcontrol
- waveRAPID
- Direct Kinetics
Products and services
- WAVEsystem (Creoptix WAVE) Next-generation bioanalytical instrument for label-free, real-time molecular interaction analysis based on proprietary Grating-Coupled Interferometry (GCI) biosensor and WAVE microfluidic technology. Provides exceptionally high sensitivity and resolution to study real-time biological interactions involving fragments, small molecules, peptides, membrane proteins, biologics and other molecules in crude reaction mixtures and biofluids including undiluted serum and plasma. Sold to pharmaceutical, biotechnology, and academic life sciences customers.
- WAVEchip microfluidic sensor chips No-clog microfluidic sensor chips designed for various analytical needs and use cases on the Creoptix WAVE instrument. Sold as recurring consumables that generate ongoing revenue tied to the installed base of WAVE instruments.
- WAVEcontrol software Fast, intuitive, automated software for instrument control and data analysis of the Creoptix WAVE system. Provides automated workflows and one-click evaluation capabilities supporting label-free molecular interaction analysis, kinetics evaluation, and binding affinity measurements for pharmaceutical, biotechnology, and academic research users.
Companies that use Creoptix
Customer profileSegments2 records
Ideal customer profiles2 records
Creoptix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Creoptix partnerships and signals
Strategic signalScale indicators2 records
Recent moves7 records
Expansion highlights5 records
Creoptix competitors and assessment
Company assessmentDirect peers
- Cytiva (Biacore): Cytiva's Biacore line is the dominant Surface Plasmon Resonance (SPR) platform for label-free molecular interaction analysis in drug discovery, directly competing with the Creoptix WAVE in pharma, biotech, and academic labs.
- Sartorius (ForteBio / Octet): Sartorius's ForteBio Octet platform uses Bio-Layer Interferometry (BLI) for label-free kinetic and binding analysis, making it one of the closest direct competitors to Creoptix WAVE in biotherapeutic characterization and drug discovery workflows.
- Nanion Technologies: Nanion provides label-free and microfluidic platforms for molecular interaction and electrophysiology analysis, overlapping with Creoptix WAVE in biophysical characterization for drug discovery and membrane-protein research.
Broad incumbents
- Molecular Devices (Danaher): Molecular Devices supplies a broad portfolio of bioanalytical and screening instruments used in drug discovery, including label-free detection and kinetic analysis systems that overlap with Creoptix's molecular interaction analysis offering.
- Bruker: Bruker is a large analytical-instruments provider with life-science and biophysical characterization products that compete in adjacent segments to Creoptix, including mass spectrometry and surface-analysis tools used in pharma R&D.
- Waters Corporation: Waters is a global analytical-instruments leader and was an investor in Creoptix's 2019 Series C; its chromatography and mass-spec portfolio overlaps with the broader bioanalytical workflow where the WAVE is positioned.
- Agilent Technologies: Agilent offers a broad portfolio of analytical instruments, separation systems, and life-science tools used by pharma and biotech customers, competing for budget allocations within the same customer labs as Creoptix.
- Revvity (formerly PerkinElmer): Revvity operates life-sciences and analytical-instruments businesses spanning detection, imaging, and bioanalytical workflows used in drug discovery and biologics development, broadly comparable to Creoptix's customer environment.
Emerging players
- Nicoya Lifesciences: Nicoya offers OpenSPR, a lower-cost, accessible SPR-based instrument for molecular interaction analysis, positioning it as an emerging alternative to Creoptix WAVE in academic and biotech labs.
- BioNavis: BioNavis provides multi-parametric surface plasmon resonance (MP-SPR) instruments for label-free interaction and kinetics analysis, representing an emerging alternative technology in the same molecular interaction analysis niche as Creoptix.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Creoptix social profiles
Digital presenceCreoptix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Creoptix leadership team
Management profileNumber of profiles
Profiles3 records
Creoptix funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Creoptix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Creoptix
What does Creoptix do?
Creoptix develops and sells the WAVE next-generation bioanalytical instrument, a label-free optical biosensor system based on proprietary Grating-Coupled Interferometry (GCI) for real-time molecular interaction analysis in drug discovery and life sciences research. The company also supplies WAVEchip microfluidic sensor chips as consumables and WAVEcontrol software for instrument control and data analysis, serving pharmaceutical, biotechnology, and academic research customers.
Is Creoptix a public or private company?
Creoptix is a private company. It is classified as corporate owned and is currently operating.
When was Creoptix founded?
Creoptix was founded in 2022. It employs 11 to 50 people.
Where is Creoptix based?
Creoptix is headquartered in Wadenswil, Switzerland, in the Europe region.
How does Creoptix make money?
Four revenue lines are on record. Bioanalytical Instruments (Hardware) is the primary driver. The others are sensor Chips and Consumables, software Licenses and Support and professional Services.
Who are Creoptix's main competitors?
Direct peers on record are Cytiva (Biacore), Sartorius (ForteBio / Octet) and Nanion Technologies. Broad incumbents are Molecular Devices (Danaher), Bruker, Waters Corporation, Agilent Technologies and Revvity (formerly PerkinElmer). Emerging players are Nicoya Lifesciences and BioNavis.
Does Creoptix have an API?
No public API is recorded for Creoptix.
What industry is Creoptix in?
Creoptix's product category is Bioanalytical Instruments. Its primary akta.pro industry code is HLAGAIAB, Mass Spectrometry & Spectroscopy Instruments. Its NAICS code is 334516 and its SIC code is 3826.